Daxor CORP Form 4 insider transactions

Daxor Corp's Chief Financial Officer, Robert J. Michel, acquired 12,000 shares of common stock, with vesting scheduled for June 23, 2026.

Daxor Corp CEO Michael Feldschuh acquired 30,000 shares of company stock, with vesting scheduled for June 23, 2026.

Daxor Corp. Chief Scientific Officer Jonathan Feldschuh acquired 25,000 shares of common stock.

Daxor Corp director Joy S. Goudie was granted stock options contingent on SEC approval of an amended incentive plan.

Daxor Corp Director Henry Cremisi was granted stock options contingent on SEC approval of an amended incentive plan.

Daxor Corp director Edward Feuer has been granted stock options contingent on SEC approval of an amended incentive plan.

Daxor Corp director Caleb DesRosiers has been granted stock options contingent on SEC approval of an amended incentive plan.

Daxor Corp CEO Michael Feldschuh acquired 1,000 shares of common stock.

Daxor Corp's Chief Financial Officer, Robert J. Michel, purchased 1,000 shares of common stock at $9.90 per share, increasing his direct beneficial ownership to 21,050 shares.

Daxor Corp's Chief Medical Officer, John Jefferies, increased his direct beneficial ownership by 5,941 shares through equity grants on March 20, 2026.

Daxor Corp's Chief Financial Officer, Robert J. Michel, has reported a planned acquisition of 3,000 shares of common stock scheduled for December 9, 2025.

Daxor Corp's Chief Scientific Officer and Director, Jonathan Feldschuh, was granted 18,000 shares of common stock, which will vest on December 9, 2025.

Daxor Corp's Chief Medical Officer, John Jefferies, was granted 2,344 shares of common stock, vesting on November 12, 2025, increasing his beneficial ownership to 17,616 shares.

Daxor Corp. Director Henry D. Cremisi was granted 2,500 stock options with an exercise price of $9.29, contingent on SEC approval of an amendment to the company's 2020 Incentive Compensation Plan.

Daxor Corp. Director Edward Feuer was granted 2,500 stock options with an exercise price of $9.29, contingent on SEC approval of an amendment to the company's 2020 Incentive Compensation Plan.

Daxor Corp. Director Joy S. Goudie was granted 2,500 stock options with an exercise price of $9.29, contingent on SEC approval of an amendment to the company's 2020 Incentive Compensation Plan.

Daxor Corp's Director, Caleb DesRosiers, was granted 2,500 stock options with an exercise price of $9.29, contingent on SEC approval of an amendment to the company's 2020 Incentive Compensation Plan.

Daxor Corp's CEO, Michael Richard Feldschuh, purchased 2,063 shares of the company's common stock at $7.89 per share on April 4, 2025.

Daxor Corp's CEO, Michael Richard Feldschuh, recently acquired 1,000 shares of Daxor Common Stock at a price of $8.13 per share.

Daxor Corp's CEO, Michael Richard Feldschuh, acquired 1,492 shares of Daxor Common Stock at $7.72 per share on March 10, 2024, increasing his direct holdings to 208,984 shares.

Daxor Corp's CEO, Michael Richard Feldschuh, acquired 647 shares of Daxor Common Stock at $8.15 per share on March 19, 2024, increasing his direct holdings to 209,631 shares.

Robert J. Michel, CFO of Daxor Corp, reports purchasing 1,000 shares of Daxor Common Stock at $8 per share on March 10, 2025.

Daxor Corp's CEO, Michael Richard Feldschuh, purchased 3,360 shares of Daxor Common Stock at $7.68 per share on March 10, 2025, increasing his direct holdings to 210,852 shares.

Daxor Corp's Chief Scientific Officer, Jonathan Adam Feldschuh, was granted 32,000 shares of common stock that vest on December 6, 2024.

Daxor Corp's CEO, Michael Feldschuh, acquired 45,000 shares of common stock through vesting on December 6, 2024.

Daxor Corp's Chief Financial Officer, Robert J. Michel, acquired 4,750 shares of common stock through vesting on December 6, 2024.

Director Caleb DesRosiers reports acquisition of stock options in Daxor Corp.

Director Joy S. Goudie reports acquisition of Daxor Corp stock options, contingent on SEC approval of plan amendment.

Director Edward Feuer of Daxor Corp reports the acquisition of stock options, contingent on SEC approval of an amendment to the company's incentive compensation plan.

Director Henry D. Cremisi of Daxor Corp reports the acquisition of stock options contingent on SEC approval of an amendment to the company's 2020 Incentive Compensation Plan.